Dopamine receptor partial agonist effect of different R amp; D with antipsychotics.docVIP

 PAGE \* MERGEFORMAT 29 Dopamine receptor partial agonist effect of different R amp; D with antipsychotics Of: the source Shijian Xi Zhou Xiaodong Liu Zhi [Keywords:] dopamine partial agonist antipsychotics direction of third-generation R amp; D Wyeth and Solvay joint development of the company’s third-generation antipsychotic drugs, dopamine partial agonists (bifeprunox, its unique characteristics of the receptor play antipsychotic effects, has been the concern of clinicians, perhaps in recent years, psychiatric the field of drug treatment occurred in a major event may change the prospects for clinical treatment. Although the drug by the U.S. Food and Drug Administration (FDA in late 2007 as part of clinical adverse reactions to verify the data has not yet been approved, this is just sooner or later thing. the drug’s unique pharmacological properties of the understanding of psychiatric drugs will help doctors to determine the direction of future research. 1 Bifeprunox metabolism of some pharmacological data 1.1 Drugs and their names Drug Name: Bifeprunox mesilate, DU 127090, chemical name: 7 [4 (Biphenyl 3 ylmethyl) piperazin 1 yl] benzoxazol 2 (3H) one methanesulfonate, Structure: Molecular formula: C24 H23 N3 O2.C H4 O3 S. 1.2 The current development status Phase III clinical trials. R amp; D companies: Solvay (Originator), Lundbeck (Licensee), Wyeth Pharmaceuticals (Licensee) .2007 In April, Colorado in the United States at the International Conference on Schizophrenia Research, according to its extrapyramidal side effects , prolactin levels, body weight, blood lipids, and other indicators of QTc interval observation that the metabolism of the drug has a good safety profile, than the current applied antipsychotics have fewer adverse reactions, is a well tolerated within the context of atypical antipsychotic drugs. Because the drug is still at the research into, the pharmacokinetics of the drug can not be publicly available data.